BicycleTX Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BicycleTX Limited - overview
Established
2009
Location
Cambridge, -, UK
Primary Industry
Biotechnology
About
BicycleTX Limited is a UK-based biopharmaceutical company focused on developing precision-guided therapeutics for solid tumors and other conditions. Its innovative technology targets hard-to-reach cancer cells, addressing significant medical needs across various therapeutic areas. BicycleTX Limited specializes in precision therapeutics to treat solid tumors and expand into related applications. Founded in 2009 in Cambridge, UK, the company has raised USD 200.
00 mn over several funding rounds, with the most recent being a Private Placement on July 12, 2023. The CEO, Kevin Lee, has a background in leading biotechnology firms, enhancing BicycleTX's strategic direction and partnerships. Bicycle Therapeutics focuses on developing precision-guided therapeutics aimed primarily at treating solid tumors while exploring applications in anti-infective, cardiovascular, ophthalmology, dementia, central nervous system, neuromuscular, and respiratory conditions. Their Bicycle® molecules are designed to penetrate tissues and target difficult cancer cells, collaborating with healthcare providers and pharmaceutical partners in North America and Europe to enhance therapeutic development.
In 2023, BicycleTX Limited reported revenues of USD 25. 86 mn, with an EBITDA of USD -194. 73 mn. The company generates revenue through strategic partnerships and collaborations, engaging in research and development agreements, licensing deals, and co-development partnerships to advance its therapeutic candidates.
BicycleTX Limited plans to leverage its recent funding of USD 200. 00 mn from a Private Placement in July 2023 to support the development of new therapeutics targeting various conditions. The company aims to expand its market reach in North America and Europe, focusing on launching innovative products within the next two years. Recent funding will enable BicycleTX to enhance its partnerships with academic and pharmaceutical institutions, ensuring the advancement of its therapeutic candidates and addressing the unmet medical needs in oncology and beyond.
Current Investors
Atlas Venture, Novartis Venture Fund, SR One
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.bicycletherapeutics.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
BicycleTX Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Exit | Completed | BicycleTX Limited | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.